$IRTC

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

Original reporting
Published Sep 3, 2026, 7:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks — source image
Decision brief

The 30-second read

$IRTCBullishMed
01

Why it matters

Earnings releases provide fresh data for short‑term trading decisions, though guidance variance creates mixed signals.

02

Market read

Earnings beats and misses across the sector create short‑term trading opportunities, but overall sentiment remains cautious.

03

What to watch

Potential supply‑chain constraints and upcoming regulatory reviews could affect future performance.

Relevance 7/10Novelty 6/10Timing: post‑earnings today

Background

The article compares Q2 results of three patient‑monitoring companies and provides brief market commentary.

Company-level read

Ticker impact

$IRTCBullishMedium confidence
Context

iRhythm reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates and raising guidance.

Expected impact

Potential modest price rally on earnings beat.

Evidence & confidence

Revenue growth and beat suggest strength, but stock fell 4.4% post‑report.

$RMDNeutralMedium confidence
Context

ResMed posted Q2 revenue of $1.46B, up 8.6% YoY, in line with expectations, with a modest EPS beat.

Expected impact

Limited price movement expected.

Evidence & confidence

Revenue in line and EPS beat, but stock rose only 3.4%.

$PODDNeutralMedium confidence
Context

Insulet reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next‑quarter guidance.

Expected impact

Possible short‑term pullback after price drop of 11.6%.

Evidence & confidence

Revenue beat is positive, yet guidance miss and price decline suggest caution.

Market effects

Patient monitoring sector shows varied performance; growth in wearables but mixed guidance.

U.S. healthcare device stocks may see divergent moves based on individual earnings.

Limited to healthcare technology investors.

Counterpoint

Despite earnings beats, price declines suggest market skepticism on sustainability of growth.

Key entities

  • iRhythm Technologies

    Wearable cardiac monitoring device maker.

  • ResMed

    Sleep apnea and respiratory disorder device manufacturer.

  • Insulet

    Insulin delivery system provider.

Related articles

$DXCMMed

A glucose sensor can be worn for up to 15.5 days. Dexcom's new monitor comes to Canada in November.

Dexcom's new G7 15 Day continuous glucose monitor, authorized by Health Canada, offers up to 15.5 days of wear and will be available in Canada in November. The company claims it is the longest-lasting and most accurate CGM system. Public and private reimbursement will be in place, making it accessible to eligible Canadians with diabetes. Dexcom aims to simplify glucose management with fewer sensor changes and reduced waste.

$DXCMMedAI 8/10

A glucose monitor added about five hours a day in target blood sugar range for people with type 2 diabetes

Dexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.